SEER is an authoratitive source of information on cancer incidence and survival in the United States. SEER currently collects and publishes cancer incidence and survival data from population-based cancer registries covering approximately 28 percent of the U.S. population.
Development of Acute myelogenous leukemia as a result of treatment for a previous malignancy with ionizing radiation or certain chemotherapy agents.
AML occurs after autologous bone marrow and stem cell transplantation; patients over 40 years at transplant who receive total body irradiation are at highest risk.
Therapy-related AML can result from chemotherapy or radiation therapy for benign or malignant diseases.
For cases abstracted prior to 2010, this code was only used for therapy-related Acute myeloid leukemia (t-AML). In the 2008 WHO Manual, this code also includes therapy-related Myelodysplastic syndrome (t-MDS) and myelodysplastic/myeloproliferative neoplasms (t-MDS-MPN) occuring as late complications of prior cytotoxic chemotherapy and/or radiation therapy administered for a neoplastic or non-neoplastic disorder. PB and BM are the principle sites of involvement.
Although WHO groups therapy-related Myelodysplastic sydrome with the therapy-related AML MDS, MPN, and MDS-MPN, the ICD-O-3 has a separate code for therapy-related MDS 9987/3. WHO has grouped these therapy-related myeloid neoplasms into one category because current clinical practice recognizes these neoplasms as being similar in etiology (therapy-related) and groups them for the purpose of analysis. Therapy-related myeloid neoplasms represent coincidental disease and would be expected to behave like other de-novo disease.
For those cases diagnosed 2010 and later, Therapy-related myelodysplasic syndrome, NOS should be coded to the 9920/3 category.
DO NOT code therapy-related myeloid neoplasm simply because the patient has a history of radiation therapy or chemotherapy. There must be a physician's statement that says this is a therapy-related neoplasm (acute myeloid leukemia, MDS, MPN, or MDS/MPN.)
Definitive Diagnostic Methods
Bone marrow with flow cytometry/cytogenetics
Alk/RT: High incidence of clonal cytogenetic abnormalities
Alk/RT: Other chromosomes include 1, 4, 12, 14, and 18
Alk/RT: Unbalanced translocations or deletions involving chromosomes 5 and/or 7
del(13q), del (20q), del(11q)m dek*3o(m -17, -18, -21, +8